Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
New England Journal of Medicine · 30.11.2023 · 389 (22) · 2039-2051
DOI: 10.1056/nejmoa2306441 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 30.11.2023. Verfasst von Caicun Zhou und 28 weiteren Autor:innen. Beteiligte Einrichtung: From Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai (C.Z.), the Division of Pulmonary and Critical Care Medicine, First …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 407-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Janssen Research and Development.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Amivantamab has been approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease progression during or after platinum-based chemotherapy. Phase 1 data showed the safety and antitumor activity of amivantamab plus carboplatin-pemetrexed (chemotherapy). Additional data on this combination therapy are needed. METHODS: In this phase 3, international, randomized trial, we assigned in a 1:1 ratio patients with advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy to receive intravenous amivantamab plus chemotherapy (amivantamab-chemotherapy) or chemotherapy alone. The primary outcome was progression-free survival according to blinded independent central review. Patients in the chemotherapy group who had disease progression were allowed to cross over to receive amivantamab monotherapy. RESULTS: A total of 308 patients underwent randomization (153 to receive amivantamab-chemotherapy and 155 to receive chemotherapy alone). Progression-free survival was significantly longer in the amivantamab-chemotherapy group than in the chemotherapy group (median, 11.4 months and 6.7 months, respectively; hazard ratio for disease progression or death, 0.40; 95% confidence interval [CI], 0.30 to 0.53; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai (C.Z.), the Division of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Sun Yat-sen University, Guangzhou (K.-J.T.), an…
ORCID-Profile: Jonathan W Goldman, Aaron S Mansfield
Förderung
- Janssen Research and Development
Zitieren
APA
Zhou, C., Tang, K. J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J. W., Sabari, J. K., Sanborn, R. E., Mansfield, A. S., Hung, J. Y., Boyer, M., Popat, S., Mourão Dias, J., Felip, E., Majem, M., Gumus, M., …, & PAPILLON Investigators (2023). Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. New England Journal of Medicine, 389(22), 2039-2051. https://doi.org/10.1056/nejmoa2306441
Vancouver
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. New England Journal of Medicine. 2023;389(22):2039-2051. doi:10.1056/nejmoa2306441
BibTeX
@article{Zhou2023,
author = {Zhou, Caicun and Tang, Ke-Jing and Cho, Byoung Chul and Liu, Baogang and Paz-Ares, Luis and Cheng, Susanna and Kitazono, Satoru and Thiagarajan, Muthukkumaran and Goldman, Jonathan W and Sabari, Joshua K and Sanborn, Rachel E and Mansfield, Aaron S and Hung, Jen-Yu and Boyer, Michael and Popat, Sanjay and Mourão Dias, Josiane and Felip, Enriqueta and Majem, Margarita and Gumus, Mahmut and Kim, Sang-We and Ono, Akira and Xie, John and Bhattacharya, Archan and Agrawal, Trishala and Shreeve, S Martin and Knoblauch, Roland E and Park, Keunchil and Girard, Nicolas and PAPILLON Investigators, PAPILLON Investigators},
title = {Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {22},
pages = {2039--2051},
doi = {10.1056/nejmoa2306441}
}
EUVIMED